Evidence map›Paper›PMID 35215268›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Synthesis and Characterization of Novel 2-Acyl-3-trifluoromethylquinoxaline 1,4-Dioxides as Potential Antimicrobial Agents.

Galina I Buravchenko, Dmitry A Maslov, Md Shah Alam, Natalia E Grammatikova, Svetlana G Frolova, Aleksey A Vatlin, Xirong Tian, Ivan V Ivanov, Olga B Bekker, Maxim A Kryakvin and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Galina I BuravchenkoGause Institute of New Antibiotics, 119021 Moscow, Russia.
Dmitry A MaslovLaboratory of Bacterial Genetics, Vavilov Institute of General Genetics, Russian Academy of Sciences, 119333 Moscow, Russia.ORCID 0000-0003-4296-5815
Md Shah AlamState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Natalia E GrammatikovaGause Institute of New Antibiotics, 119021 Moscow, Russia.
Svetlana G FrolovaLaboratory of Bacterial Genetics, Vavilov Institute of General Genetics, Russian Academy of Sciences, 119333 Moscow, Russia.
Aleksey A VatlinLaboratory of Bacterial Genetics, Vavilov Institute of General Genetics, Russian Academy of Sciences, 119333 Moscow, Russia.
Xirong TianState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Ivan V IvanovGause Institute of New Antibiotics, 119021 Moscow, Russia.
Olga B BekkerLaboratory of Bacterial Genetics, Vavilov Institute of General Genetics, Russian Academy of Sciences, 119333 Moscow, Russia.
Maxim A KryakvinChemistry Department, Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119991 Moscow, Russia.
Olga A DontsovaChemistry Department, Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119991 Moscow, Russia.
Valery N DanilenkoLaboratory of Bacterial Genetics, Vavilov Institute of General Genetics, Russian Academy of Sciences, 119333 Moscow, Russia.
Tianyu ZhangState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.ORCID 0000-0001-5647-6014
Andrey E ShchekotikhinGause Institute of New Antibiotics, 119021 Moscow, Russia.ORCID 0000-0002-6595-0811
Chinese Academy of Sciences · CNGause Institute of New Antibiotics Russian Academy of Medical Sciences · RUVavilov Institute of General Genetics · RUD. Mendeleyev University of Chemical Technology of Russia · RULomonosov Moscow State University · RUMoscow Institute of Physics and Technology · RUPeoples' Friendship University of Russia · RUSkolkovo Institute of Science and Technology · RU

Funding

National Natural Science Foundation of China 82061138019Russian Science Foundation 21-45-00018Russian Science Foundation 21-64-00006the National Key R&D Program of China 2021YFA1300904
6 · The paper itself

Abstract

The emergence of drug resistance in pathogens leads to a loss of effectiveness of antimicrobials and complicates the treatment of bacterial infections. Quinoxaline 1,4-dioxides represent a prospective scaffold for search of new compounds with improved chemotherapeutic characteristics. Novel 2-acyl-3-trifluoromethylquinoxaline 1,4-dioxides with alteration of substituents at position 2 and 6 were synthesized via nucleophilic substitution with piperazine moiety and evaluated against a broad panel of bacteria and fungi by measuring their minimal inhibitory concentrations. Their mode of action was assessed by whole-genomic sequencing of spontaneous drug-resistant

Indexed as

3-trifluoromethylquinoxaline 1,4-dioxidesantimicrobial activityDNA-damaging agentsM. smegmatis mutantsstructure–activity relationships

Identifiers

PMID35215268
PMCPMC8877263
OpenAlexW4210297649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.